KUALA LUMPUR: Duopharma Biotech Bhd
achieved higher earnings in the first quarter ended March 31, 2026, underpinned by a stronger ringgit, coupled with lower operating expenses and net finance cost.
The pharmaceutical company reported net profit of RM30.71mil in 1QFY26, which was an improvement over RM25.64mil in the year-ago quarter. During the period, the stronger domestic currency helped to ease active pharmaceutical ingredient (API) input costs, which led to a higher profit.
This was despite quarterly revenue declining to RM247.88mil from RM262.74mil in the previous corresponding quarter, as demand for insulin products normalised to regular levels following a one-off surge in 1QFY25.
However, the group noted revenue was suported by growth in the private and export segments, driven in part by a strong performance in the consumer healthcare business.
Duopharma Biotech group CEO Wan Amir-Jeffery Wan Abdul Majid said the group anticipates a favourable operating environment in
light of the deliberate emphasis on expanding local pharmaceutical manufacturing capabilities, as indicated in the 13th Malaysia Plan and the New Industrial Master Plan 2030.
"As a leading homegrown pharmaceutical manufacturer in Malaysia, Duopharma Biotech is uniquely positioned to capitalise on these structural opportunities.
"At the same time, to safeguard continuity of production during global macroeconomic and geopolitical volatility, we have proactively strengthened our supply chain resilience through strategic inventory management, diversification of API sourcing and close engagement with key suppliers.”
